Lallemand, GM Pharmaceuticals launch Ismigen in Georgia
Lallemand Pharma and GM Pharmaceuticals have introduced new oral vaccine Ismigen in Georgia, US, to prevent acute exacerbations in chronic obstructive pulmonary disease.
Lallemand Pharma and GM Pharmaceuticals have introduced new oral vaccine Ismigen in Georgia, US, to prevent acute exacerbations in chronic obstructive pulmonary disease.
Ismigen, a polyvalent mechanical bacterial lysate, is also used to prevent acute, sub-acute, recurrent or chronic infections of the upper and lower airways and the bronchopulmonary tree.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The drug is prepared from a large array of inactivated pathogenic bacteria via mechanical lysis.
Switzerland-based Lallemand Pharma’s key products are comprised of immunostimulant drugs Ismigen, Immubron and Respibron, which target infections of the respiratory tract.
Sign up for our daily news round-up!
Give your business an edge with our leading industry insights.
Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.
Excellence in Action Recognised with 2025 Excellence Awards for Research and Development and Marketing, Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.
